Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses
The findings of this cohort study demonstrate that drug prices were reduced substantially after patent expirations in high-income countries. Therefore, incorporating information on patent status and pricing dynamics in cost-effectiveness assessment analyses is necessary for producing accurate economic evaluations of new drugs.
Authors
- Kerstin Noëlle Vokinger (ORCID: https://orcid.org/0000-0002-6997-7384)
- Miquel Serra‐Burriel (ORCID: https://orcid.org/0000-0001-8595-1224)
- Nicolau Martin‐Bassols (ORCID: https://orcid.org/0000-0003-1770-5990)
- Gellért Perényi
Institutions
- University of Zurich (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- University of Bologna (IT)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.2530
- Citations
- 9
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 11.29
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung